Blue Water Vaccines Announces Exploration of Its Virus-Like Particle (VLP) Platform for Use in Monkeypox Vaccine Candidate
August 17 2022 - 8:30AM
Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or “the
Company”), a biopharmaceutical company developing transformational
vaccines to address significant global health challenges, today
announced that the Company plans to explore the potential to
develop a novel monkeypox vaccine using its norovirus shell and
protrusion (S&P) virus-like particle (VLP) platform.
The Company’s S&P platform is currently being utilized to
develop vaccine candidates across multiple diseases, including
BWV-101 for influenza, BWV-301 for gastroenteritis via norovirus or
rotavirus infection, and BWV-302 for malaria. In this new effort,
BWV will attempt to present monkeypox antigens within the S&P
platform to potentially create a vaccine candidate capable of
protecting individuals against monkeypox disease.
“As monkeypox cases rise around the globe, BWV is committed to
exploring the potential of our platform to create a novel monkeypox
vaccine candidate,” said Joseph Hernandez, Chairman and Chief
Executive Officer of Blue Water Vaccines. “Our VLP platform has
previously demonstrated versatility across multiple infectious
diseases, and we are excited to initiate this research to
understand the potential to create another vaccine to fight this
outbreak.”
In July 2021, Blue Water Vaccines entered an exclusive, global
licensing agreement with Cincinnati Children’s to develop vaccines
for multiple infectious diseases utilizing the latter’s novel
virus-like particle (VLP) vaccine platform. The platform leverages
norovirus capsid proteins to present foreign antigens for immune
enhancement.
According to the World Health Organization, monkeypox is a virus
transmitted to humans from animals, with clinical symptoms like
those seen in smallpox patients. Human-to-human transmission can
result from close contact with respiratory secretions, skin lesions
of an infected person, or recently contaminated objects. According
to the Centers for Disease Control and Prevention, there have been
about 12,000 reported cases of monkeypox in the United States
between May and August 2022. There are two vaccines approved for
prevention of monkeypox disease in the United States, but limited
availability of either vaccine has resulted in increasing cases
within the US and globally.
About Blue Water Vaccines
Blue Water Vaccines Inc. is a biopharmaceutical company focused
on developing transformational vaccines to address significant
health challenges globally. Headquartered in Cincinnati, OH, the
company holds the rights to proprietary technology developed at the
University of Oxford, Cincinnati Children's Hospital Medical
Center, and St. Jude Children's Hospital. The company is developing
a universal flu vaccine that will provide protection from all
virulent strains in addition to licensing a novel norovirus (NoV)
S&P nanoparticle versatile virus-like particle (VLP) vaccine
platform from Cincinnati Children’s to develop vaccines for
multiple infectious diseases, including norovirus/rotavirus and
malaria, among others. Additionally, Blue Water Vaccines is
developing a Streptococcus pneumoniae (pneumococcus) vaccine
candidate, designed to specifically prevent the highly infectious
middle ear infections, known as Acute Otitis Media (AOM), in
children. For more information, visit
www.bluewatervaccines.com.
Forward-Looking Statements
Certain statements in this press release are forward-looking
within the meaning of the Private Securities Litigation Reform Act
of 1995. These statements may be identified by the use of
forward-looking words such as “anticipate,” “believe,” “forecast,”
“estimate,” “expect,” and “intend,” among others. These
forward-looking statements are based on BWV’s current expectations
and actual results could differ materially. There are a number of
factors that could cause actual events to differ materially from
those indicated by such forward-looking statements. These factors
include, but are not limited to, risks related to the development
of BWV’s vaccine candidates; the failure to obtain FDA clearances
or approvals and noncompliance with FDA regulations; delays and
uncertainties caused by the global COVID-19 pandemic; risks related
to the timing and progress of clinical development of our product
candidates; our need for additional financing; uncertainties of
patent protection and litigation; uncertainties of government or
third party payor reimbursement; limited research and development
efforts and dependence upon third parties; and substantial
competition. As with any vaccine under development, there are
significant risks in the development, regulatory approval and
commercialization of new products. BWV does not undertake an
obligation to update or revise any forward-looking statement.
Investors should read the risk factors set forth in BWV’s Annual
Report on Form 10-K for the fiscal year ended December 31, 2021,
filed with the Securities and Exchange Commission (the “SEC”) on
March 31, 2022, Quarterly Report on Form 10-Q for the quarter ended
June 30, 2022, filed with the SEC on August 15, 2022 and periodic
reports filed with the SEC on or after the date thereof. All of
BWV’s forward-looking statements are expressly qualified by all
such risk factors and other cautionary statements. The information
set forth herein speaks only as of the date thereof.
Media Contact Information:Blue Water Media
RelationsTelephone: (646) 942-5591 Email:
Nic.Johnson@russopartnersllc.com
Investor Contact Information:Blue Water Investor RelationsEmail:
investors@bluewatervaccines.com
Blue Water Biotech (NASDAQ:BWV)
Historical Stock Chart
From Aug 2024 to Sep 2024
Blue Water Biotech (NASDAQ:BWV)
Historical Stock Chart
From Sep 2023 to Sep 2024